Topics

Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints

06:49 EDT 13 Sep 2019 | Pharmaceutical Business Review

The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML) who achieved first complete response

The post Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints appeared first on Pharmaceutical Business review.

Original Article: Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints

NEXT ARTICLE

More From BioPortfolio on "Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints"

Quick Search